Published in Early Interv Psychiatry on February 01, 2010
Effects of paliperidone extended release on the symptoms and functioning of schizophrenia. BMC Clin Pharmacol (2012) 0.90
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatr Dis Treat (2012) 0.88
Paliperidone extended-release: does it have a place in antipsychotic therapy? Drug Des Devel Ther (2011) 0.84
Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial. Ther Adv Psychopharmacol (2011) 0.84
Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach. Int Clin Psychopharmacol (2015) 0.75
Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia. Ther Adv Psychopharmacol (2015) 0.75
Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry (2008) 9.54
The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 4.16
North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull (2007) 3.28
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry (2009) 3.26
The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr Res (2010) 2.78
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry (2005) 2.39
Limited utility of number needed to treat and the polarity index for bipolar disorder to characterize treatment response. Eur Neuropsychopharmacol (2013) 2.14
A discussion of 2 double-blind studies comparing risperidone and quetiapine in patients with schizophrenia. J Clin Psychiatry (2007) 1.99
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res (2006) 1.93
Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement (2011) 1.81
Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Early Interv Psychiatry (2010) 1.71
Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry (2009) 1.61
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology (2006) 1.59
A preliminary meta-analysis of the child behavior checklist in pediatric bipolar disorder. Biol Psychiatry (2003) 1.58
Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med (2007) 1.57
Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry (2015) 1.55
Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr Bull (2006) 1.54
Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res (2004) 1.49
High dose D-serine in the treatment of schizophrenia. Schizophr Res (2010) 1.33
A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry (2006) 1.31
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr Res (2005) 1.27
Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside Adolescent High Risk Studies. Schizophr Bull (2006) 1.26
Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord (2009) 1.20
The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr Bull (2007) 1.19
A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia. Psychiatry (Edgmont) (2010) 1.18
Spatial working memory deficits in adolescents at clinical high risk for schizophrenia. Schizophr Res (2006) 1.06
A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry (2010) 1.04
Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry (2006) 1.04
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry (2012) 1.02
Scales as outcome measures for Alzheimer's disease. Alzheimers Dement (2009) 1.02
Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord (2007) 1.01
Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol (2005) 1.01
Caudate nucleus volume and cognitive performance: Are they related in childhood psychopathology? Biol Psychiatry (2006) 1.00
Reliability of neuroanatomical measurements in a multisite longitudinal study of youth at risk for psychosis. Hum Brain Mapp (2013) 0.99
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord (2009) 0.97
Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry (2004) 0.96
Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol (2010) 0.96
Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res (2005) 0.96
Gender and schizophrenia. Psychopharmacol Bull (2007) 0.96
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol. Am J Psychiatry (2006) 0.95
Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol (2008) 0.95
Sexual dimorphisms and prediction of conversion in the NAPLS psychosis prodrome. Schizophr Res (2013) 0.95
Anterior cingulate volume in pediatric bipolar disorder and autism. J Affect Disord (2007) 0.94
Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord (2004) 0.94
Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale. Psychopathology (2008) 0.93
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry (2004) 0.91
Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. Int Clin Psychopharmacol (2014) 0.90
Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol (2007) 0.90
Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. Int Clin Psychopharmacol (2006) 0.90
Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. Neuropsychiatr Dis Treat (2008) 0.89
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry (2004) 0.89
Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Alzheimer Dis Assoc Disord (2008) 0.88
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatr Dis Treat (2012) 0.88
Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study. Alzheimer Dis Assoc Disord (2005) 0.87
Role of paliperidone extended-release in treatment of schizoaffective disorder. Neuropsychiatr Dis Treat (2010) 0.87
Prepsychotic phase of schizophrenia and related disorders: recent progress and future opportunities. Br J Psychiatry Suppl (2005) 0.87
Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. Int Clin Psychopharmacol (2010) 0.86
Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study. Ann Gen Psychiatry (2009) 0.86
Onset and persistence of antipsychotic response in patients with schizophrenia. J Clin Psychopharmacol (2009) 0.86
Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry (2011) 0.86
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res (2005) 0.85
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry (2004) 0.85
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry (2013) 0.85
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. Neuropsychiatr Dis Treat (2013) 0.84
Psychotic symptoms in patients with bipolar mania. J Affect Disord (2008) 0.84
Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials. Drugs Aging (2007) 0.84
Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res (2005) 0.84
The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J Nerv Ment Dis (2007) 0.84
Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol (2004) 0.83
Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC Psychiatry (2011) 0.83
Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC Psychiatry (2011) 0.83
Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Ann Clin Psychiatry (2007) 0.81
A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry (2014) 0.81
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry (2007) 0.81
Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder. J Child Adolesc Psychopharmacol (2009) 0.80
Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophr Res (2011) 0.80
Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis (2007) 0.80
Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. Schizophr Res (2012) 0.80
An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol (2013) 0.79
Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale. Innov Clin Neurosci (2012) 0.79
Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol (2005) 0.79
A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innov Clin Neurosci (2011) 0.79
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry (2007) 0.79